Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Boston , US
Biotech
Therapeutics
Drug discovery
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
🏳️
Claim This ListingIs this your company?
Claim this listing to manage your profile, add updates, and connect with your audience.
